Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: Current evidence and future perspectives

Expert Review of Anticancer Therapy

Volumn 13, Issue 10, 2013, Pages 1207-1218

  Costanzo, Raffaele ^a   Montanino, Agnese ^a   Di Maio, Massimo ^a   Piccirillo, Maria Carmela ^a   Sandomenico, Claudia ^a   Giordano, Pasqualina ^a   Daniele, Gennaro ^a   Franco, Renato ^a   Perrone, Francesco ^a   Rocco, Gaetano ^a   Normanno, Nicola ^a,b   Morabito, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Centro di Ricerche Oncologiche di Mercogliano CROM   (Italy)

Author keywords

afatinib; clinical trials; dacomitinib; EGFR; erlotinib; gefitinib; neratinib; NSCLC

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NERATINIB; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BIM GENE; BRAF GENE; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EGFR GENE; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HER2 GENE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAPK1 GENE; MET GENE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PARONYCHIA; PIK3CA GENE; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84886390038     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.845092     Document Type: Review

References (75)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Med. 350(21), 2129-2139 (2004).
2. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
3. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
4. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21(14), 2787-2799 (2003).
5. Ciardiello F, Tortora G. EGFR Antagonist in Cancer Treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
6. Voon PJ, Cho BC, Yeo WL, Soo RA. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J. Thorac. Dis. 2(3), 144-153 (2010).
7. Morabito A, Piccirillo MC, Monaco K et al. Methodological issues of clinical research with EGFR inhibitors. Curr. Cancer Ther. Rev. 3, 292-302 (2007).
8. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J. Natl Cancer Inst. 97(5), 339-346 (2005).
9. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25(5), 587-595 (2007).
10. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760-774 (2010).
11. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 (Suppl. 1), S24-S31 (2009).
12. Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 11(3), 217-227 (2007).
13. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
14. Costanzo R, Piccirillo MC, Sandomenico C et al. Gefitinib in non-small cell lung cancer. J. Biomed. Biotechnol. 2011, 815269 (2011).
15. Sequist LV, Martins RG, Spigel D et al First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26(15), 2442-2449 (2008).
16. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
17. Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J. Clin. Oncol. 30(10), 1122-1128 (2012).
18. Mitsudomi T, Morita S, Negoro S et al Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
19. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010)
20. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29(21), 2866-2874 (2012).
21. Thongprasert S, Duffield E, Saijo N et al Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J. Thorac. Oncol 6(11), 1872-1880 (2011).
22. Douillard JY, Ostoros G, Cobo M et al. Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Lung Cancer. 80 (Suppl. 1), S31 (2013).
23. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
24. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
25. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
26. Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann. Oncol. 24(6), 1615-1622 (2013).
27. Zhou C, Wu YL, Liu X et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). 2012 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2012 (Abstract 7520).
28. Kim ST, Uhm JE, Lee J et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75(1), 82-88 (2012).
29. Bean J, Riely GJ, Balak M et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14(22), 7519-7525 (2008).
30. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008).
31. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102(21), 7665-7670 (2005).
32. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 13(5), 539-548 (2012).
33. Sequist LV, Yang J-CH, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013).
34. Wu YL, Zhou C, Hu CP et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J. Clin. Oncol. 31(Suppl.), Abstract 8016 (2013).
35. Greater SL, Zhou C, Hu CP et al. LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations. J. Clin. Oncol. 31(Suppl.), Abstract 8061 (2013).
36. Janne P, Reckamp K, Koczywas M et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J. Clin. Oncol. 27 (Suppl.), 15s, Abstract 8063 (2009)
37. Ramalingam SS, Blackhall F, Krzakowski M et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 30(27), 3337-3344 (2012).
38. Sequist LV, Beese B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28(18), 3076-3083 (2010).
39. Gong Y, Somwar R, Politi K et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4(10), e294 (2007).
40. Rosell R, Molina MA, Costa C et al. Pretreatment EGFR T790M mutation and BRAC1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 17(5), 1160-1168 (2011).
41. Bivona TG, Hieronymus H, Parker J et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339), 523-526, (2011).
42. Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28(2), 357-360 (2010).
43. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
44. Kosaka T, Yatabe Y, Endoh H et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12(19), 5764-5769 (2006).
45. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 105(6), 2070-2075 (2008).
46. Wu JY, Wu SG, Yang CH et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin. Cancer Res. 14(15), 4877-4882 (2008).
47. Morabito A, Costanzo R, Rachiglio AM, et al. Activity of Gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. J. Thorac. Oncol. 8(7), e59-e60 (2013).
48. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
49. Takezawa K, Pirazzoli V, Arcila ME et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2(10), 922-933 (2012).
50. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
51. Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109(31), E2127-E2133 (2012).
52. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44(8), 852-860 (2012).
53. Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2(10), 934-947 (2012).
54. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31(8), 1070-1080 (2013).
55. Togashi Y, Masago K, Fukudo M et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother. Pharmacol. 68(4), 1089-1092 (2011).
56. Heon S, Yeap BY, Britt GJ et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 16(23), 5873-5882 (2010).
57. Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 79(1), 33-39 (2013).
58. West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. ASCO Educational Book. Am. Soc. Clin. Oncol. e272-e278 (2013).
59. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl Cancer Inst. 105(9), 595-605 (2013).
60. Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference? J. Clin. Oncol. 31(8), 1081-1088 (2013).
61. Gridelli C, Ciardiello F, Gallo C et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J. Clin. Oncol. 30(24), 3002-3011 (2012).
62. Nishino M, Cardarella S, Dahlberg SE et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79(3), 283-288 (2013).
63. Chmielecki J, Foo J, Oxnard GR et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelling. Sci. Transl. Med. 3(90), 90ra59 (2011).
64. Asahina H, Oizumi S, Inoue A et al. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 79(5-6), 423-429 (2010).
65. Becker A, Crombag L, Heideman DA et al. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer. 47(17), 2603-2606 (2011).
66. Ercan D, Zejnullahu K, Yonesaka K et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29(16), 2346-2356 (2010).
67. Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276), 1070-1074 (2009).
68. Walter AO, Tjin R, Haringsma H et al. CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations. Mol. Cancer Ther. 10 (11 Suppl. 1), C189 (2011).
69. Rivera VM, Wang F, Anjum R et al. AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Res. 72(Suppl. 72), 1794 (2012).
70. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17(17), 5530-5537 (2011).
71. Groen HJ, Horn L, Smit EF et al. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. Presented at: 14th World Conference on Lung Cancer. Amsterdam, NL, 3-7 July 2011.
72. Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 27(9), 1394-1400 (2009).
73. Morabito A, Sandomenico C, Costanzo R et al. Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib. J. Thorac. Oncol. 7(11), e27-e28 (2012).
74. Porta R, Sánchez-Torres JM, Paz-Ares L et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur. Respir. J. 37(3), 624-631 (2011).
75. Park SJ, Kim HT, Lee DH et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77(3), 556-560 (2012).